文献速递妇科

良性子宫切除术中药理静脉血栓栓塞预防的效果

Effects of Pharmacologic Venous Thromboembolism Prophylaxis in Benign Hysterectomy.
PubMed 文献 · J Minim Invasive Gynecol · 2022-02-26

该回顾性队列研究基于密歇根外科质量协作数据库,比较单纯机械预防与机械加药物双预防在良性子宫切除术中的围手术期结局。在微创手术中双预防组手术时间延长18.3分钟,在开腹手术中延长15.3分钟且估计失血量增加54.5 mL,其他次要结局无差异。

要点

  • 微创子宫切除术中,双预防组手术时间较单纯机械预防组延长18.3分钟(95%CI 13.8-22.8)。
  • 开腹子宫切除术中,双预防组估计失血量较单纯机械预防组增加54.5 mL(95%CI 16.9-92.1)。
  • 鉴于静脉血栓栓塞发生率极低且可能存在伤害,作者认为对接受机械预防的良性子宫切除术患者应个体化而非常规使用药物预防。

核心结论

  • 在良性子宫切除术中,在机械预防基础上加用药物预防与手术时间延长相关,且开腹子宫切除术中估计失血量增加。
  • 鉴于静脉血栓栓塞发生率极低、其他围手术期结局无差异以及可能的伤害,作者认为对接受机械预防的良性子宫切除术患者应鼓励个体化而非常规使用药物预防。

研究设计与样本

  • 回顾性队列研究,数据来源于密歇根外科质量协作数据库。
  • 纳入2012年7月至2015年6月期间接受子宫切除术且收集了静脉血栓栓塞预防数据的患者。
  • 比较单纯机械预防组与双预防组(机械联合药物预防),微创手术与开腹手术分开分析。
  • 采用倾向性评分匹配以减少人口学和围手术期特征差异所致的混杂。
  • 微创手术分析有1803对匹配;开腹手术分析采用2:1匹配,单纯机械预防组1168例匹配双预防组616例。

主要发现

  • 微创手术分析中,双预防组与单纯机械预防组估计失血量无差异。
  • 开腹手术分析中,双预防组估计失血量较单纯机械预防组增加54.5 mL(95%CI 16.9-92.1)。
  • 微创手术中,双预防组手术时间较单纯机械预防组延长18.3分钟(95%CI 13.8-22.8)。
  • 开腹手术中,双预防组手术时间较单纯机械预防组延长15.3分钟(95%CI 9.0-21.6)。
  • 其他次要结局(术后输血、静脉血栓栓塞、手术部位感染、再手术、再入院和死亡)两组间无差异。

临床怎么用

  • 作者认为,对接受机械预防的良性子宫切除术患者,应鼓励个体化而非常规使用药物预防。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY OBJECTIVE: To evaluate whether the addition of pharmacologic prophylaxis to mechanical prophylaxis for venous thromboembolism (VTE) is associated with changes in perioperative outcomes in hysterectomy for benign indications. DESIGN: Retrospective cohort study. SETTING: Michigan Surgical Quality Collaborative database. PATIENTS: Patients who underwent hysterectomy between July 2012 and June 2015 when VTE prophylaxis data were collected. INTERVENTIONS: Patients who received mechanical prophylaxis alone were compared with those receiving dual prophylaxis (mechanical and pharmacologic). Minimally invasive surgeries (MIS) included laparoscopic, vaginal, robotic-assisted, and laparoscopic-assisted vaginal hysterectomies and were analyzed separately from abdominal (ABD) hysterectomy. MEASUREMENTS AND MAIN RESULTS: Propensity score matching was used to minimize confounding because of the differences in demographic and perioperative characteristics. The primary outcome was estimated blood loss (EBL). The secondary outcomes were operative time, postoperative blood transfusion, VTE, surgical site infection, reoperation, readmission, and death. There were 1803 matched pairs in the MIS analysis. In the ABD hysterectomy analysis, 2:1 matching was used with a total of 1168 patients receiving mechanical prophylaxis alone matched to 616 patients receiving dual prophylaxis. EBL was higher by 54.5 mL (95% confidence interval [CI], 16.9-92.1) in those receiving dual prophylaxis in the ABD hysterectomy analysis but did not differ between groups in the MIS analysis. Operative time was significantly longer with dual prophylaxis in both MIS (18.3 minutes; 95% CI, 13.8-22.8) and ABD (15.3 minutes; 95% CI, 9.0-21.6) surgical approaches. There was no difference in other secondary outcomes. CONCLUSION: The addition of pharmacologic prophylaxis to mechanical prophylaxis in benign hysterectomy was associated with longer operative time, regardless of surgical approach and increased EBL in ABD hysterectomy. Given very low rates of VTE, no difference in other perioperative outcomes, and possible harm, it seems reasonable to encourage individualized rather than routine use of pharmacologic prophylaxis in patients undergoing benign hysterectomy receiving mechanical prophylaxis.

来源:J Minim Invasive Gynecol,查看原文。版权归原作者所有。

引用

  1. Travieso J, Kamdar N, Morgan DM, et al. Effects of Pharmacologic Venous Thromboembolism Prophylaxis in Benign Hysterectomy. J Minim Invasive Gynecol. 2022. PMID: 35227913. doi:10.1016/j.jmig.2022.02.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。